

July 13, 2017

[Press Release]

Nichi-Iko Pharmaceutical Co., Ltd.
Yakuhan Pharmaceutical Co., Ltd.
AYUMI Pharmaceutical Corporation

Licensing Agreement for Marketing Rights to Infliximab BS for I.V. Infusion 100mg “AYUMI”

Nichi-Iko Pharmaceutical Co., Ltd. (Head office: Toyama-shi, Toyama Prefecture, President & CEO Yuichi Tamura), Yakuhan Pharmaceutical Co., Ltd. (Head office: Kitahiroshima-shi, Hokkaido, Representative Director Toru Kanazawa, 100% subsidiary of Nichi-Iko), and AYUMI Pharmaceutical Corporation (Head office: Chuo-ku, Tokyo, President Hikaru Ouchi) today announced that the companies have reached a licensing agreement to grant marketing rights for Infliximab BS for I.V. Infusion 100mg “AYUMI,” for which Yakuhan Pharmaceutical Co., Ltd. is seeking manufacturing and marketing approval, to AYUMI Pharmaceutical Corporation, when that approval is obtained.

END

Contacts for Inquiries	
AYUMI Pharmaceutical Corporation Corporate Planning Department Tel: 03-6264-3525	Nichi-Iko Pharmaceutical Co., Ltd. President Office Tel: 076-442-7026